News InflaRx stock halves after it drops lead drug InflaRx has abandoned its drug development programme, vilobelimab for rare skin disease pyoderma gangrenosum, cratering its share price.
News FDA greenlights Regeneron drug for rare bone disease Regeneron's Pasatru will be the second FDA-approved treatment for fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
